Serum albumin and CA125 are powerful predictors of survival in epithelial ovarian cancer
- 1 October 1994
- journal article
- Published by Wiley in BJOG: An International Journal of Obstetrics and Gynaecology
- Vol. 101 (10) , 888-893
- https://doi.org/10.1111/j.1471-0528.1994.tb13550.x
Abstract
Objective To assess the prognostic significance of presentation serum albumin, clinical stage and CA125 levels in ovarian cancer. Design Retrospective analysis of data using a Cox proportional hazards model. Setting A district general hospital oncology unit. Subject One hundred and fourteen consecutive patients with epithelial ovarian cancer. Interventions Cytotoxic chemotherapy and surgery. Main outcome measure Survival. Results A linear increase in risk was observed with high log CA125 (P < 0.0001) and with low albumin (P < 0.0001). In late stage patients (III and IV) albumin is the best predictor of survival (P= 0.0006). The presence of ascites, blood transfusion, type of surgery or chemotherapy did not improve the predictive model. Conclusions CA125 and albumin can be used to identify prognostic subgroups independently of stage. Albumin alone can also be used as a predictor of survival. A simple classification of patients into three groups based on serum albumin of 41 g/l or more, 35 to 40 g/l and 34 g/l or less provides a clear separation of survival curves in the present group of patients.Keywords
This publication has 18 references indexed in Scilit:
- WednesdayAnnals of Oncology, 1992
- Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1991
- Oestrogen and progesterone receptor content as a prognostic factor in advanced epithelial ovarian carcinomaBJOG: An International Journal of Obstetrics and Gynaecology, 1990
- Adjuvant Therapy in Stage I and Stage II Epithelial Ovarian CancerNew England Journal of Medicine, 1990
- Adjuvant Therapy for Early-Stage Ovarian CancerNew England Journal of Medicine, 1990
- Serum albumin: Its relationship to marrow and renal toxicity from platinum-based combination chemotherapyGynecologic Oncology, 1990
- The prognostic significance of the half‐life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinomaBJOG: An International Journal of Obstetrics and Gynaecology, 1989
- CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1989
- DNA flow cytometry and morphometry as prognostic indicators in advanced ovarian cancer: A step forward in predicting the clinical outcomeGynecologic Oncology, 1988
- Reactivity of a monoclonal antibody with human ovarian carcinoma.Journal of Clinical Investigation, 1981